
Opinion|Videos|June 14, 2024
Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
Heidi Crayton, MD, and Maria Lopes, MD, discuss the limitations of using relapse rates as a critical endpoint in trials for patients with non-relapsing secondary progressive multiple sclerosis experiencing disease progression without relapse, explore methods to assess therapeutic benefit in this population, examine the relationship between cost of care and disease severity, and highlight the impact of decreased mobility and cognition on MS patients along with strategies for improvement.
Advertisement
Episodes in this series

- Relapse rates have traditionally been viewed as a critical endpoint for previous MS trials, which are not applicable in patients with non-relapsing secondary progressive multiple sclerosis with disease progression without relapse. How do you determine whether a patient is benefitting from therapy in this patient population?
- What is the relationship of costs of
care and disease severity in patients with MS, and how do payers view the current costs of care for patients with MS? - What is the impact of decreased mobility and cognition on patients with MS, and what are some strategies to help improve it?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
4
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
5


